Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet medical need in the United States. To meet the demand for new treatments, companies in America’s biopharmaceutical industry have spent years working across the biomedical ecosystem to research and develop new medicines that employ the latest in scientific and technical knowledge.
